Adipose targets for obesity drug development

被引:13
作者
Boss, O [1 ]
Bergenhem, N [1 ]
机构
[1] Adipogenix Inc, Boston, MA 02118 USA
关键词
11 beta-hydroxysteroid dehydrogenase type (11 beta-HSD1); acylation-stimulating protein (ASP); acyl-CoA : diacylglycerol acyltransferase (DGAT1); adiponectin; beta 3-adrenergic receptor; (beta 3-AR); insulin resistance; leptin; obesity; oestrogen-related receptor (ERR); perilipin; peroxisome proliferator-activated receptor (PPAR); protein tyrosine phosphatase-1B (PTP-1B); stearoyl-CoA desaturase-1 (SCD1);
D O I
10.1517/14728222.10.1.119
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The prevalence of obesity is increasing rapidly in most parts of the world and effective therapeutic drugs are urgently needed. The discovery of leptin in 1994 initiated a new understanding of adipose tissue function, and adipose tissue is now known to not only store and release fatty acids, but also to produce a wealth of factors that have an impact on the regulation of body weight and blood glucose homeostasis. Also, adipocytes express proteins that engage signalling pathways playing important roles in fuel substrate and energy metabolism. These proteins constitute a diverse array of adipose target candidates for the development of drugs to treat obesity. Some of these potential targets have been validated and are now in drug development stages, providing hope that the current obesity epidemic can be addressed by effective drug treatments in the near future.
引用
收藏
页码:119 / 134
页数:16
相关论文
共 160 条
[1]   INTERLEUKIN-1 RECEPTOR ANTAGONIST - A NEW MEMBER OF THE INTERLEUKIN-1 FAMILY [J].
AREND, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1445-1451
[2]   Peroxisome proliferator-activated receptor γ:: the more the merrier? [J].
Argmann, CA ;
Cock, TA ;
Auwerx, J .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2005, 35 (02) :82-92
[3]   Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients [J].
Bajaj, M ;
Suraamornkul, S ;
Piper, P ;
Hardies, LJ ;
Glass, L ;
Cersosimo, E ;
Pratipanawatr, T ;
Miyazaki, Y ;
Defronzo, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :200-206
[4]  
BALKAN B, 2004, DIABETES S2, V53, pP618
[5]   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953
[6]   Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator [J].
Berger, JP ;
Petro, AE ;
Macnaul, KL ;
Kelly, LJ ;
Zhang, BB ;
Richards, K ;
Elbrecht, A ;
Johnson, BA ;
Zhou, GC ;
Doebber, TW ;
Biswas, C ;
Parikh, M ;
Sharma, N ;
Tanen, MR ;
Thompson, GM ;
Ventre, J ;
Adams, AD ;
Mosley, R ;
Surwit, RS ;
Moller, DE .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (04) :662-676
[7]   PPARs: therapeutic targets for metabolic disease [J].
Berger, JP ;
Akiyama, TE ;
Meinke, PT .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251
[8]   Energy expenditure of Rhesus monkeys subjected to 11 years of dietary restriction [J].
Blanc, S ;
Schoeller, D ;
Kemnitz, J ;
Weindruch, R ;
Colman, R ;
Newton, W ;
Wink, K ;
Baum, S ;
Ramsey, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) :16-23
[9]   The effects of K-111, a new insulin-sensitizer, on metabolic syndrome in obese prediabetic rhesus monkeys [J].
Bodkin, NL ;
Pill, J ;
Meyer, K ;
Hansen, BC .
HORMONE AND METABOLIC RESEARCH, 2003, 35 (10) :617-624
[10]   Adiponectin:: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? [J].
Bouskila, M ;
Pajvani, UB ;
Scherer, PE .
INTERNATIONAL JOURNAL OF OBESITY, 2005, 29 (Suppl 1) :S17-S23